melanoma – Medxy AI

Long-Term Real-World Outcomes of Adjuvant Anti-PD-1 Checkpoint Inhibition Versus Targeted Therapy in Stage III Melanoma: A Comprehensive Review

By MedXY 09/09/2025

This review synthesizes current evidence on long-term real-world efficacy of adjuvant anti-PD-1 immunotherapy and targeted BRAF/MEK inhibitor therapy in stage III melanoma, highlighting differential recurrence risks, survival benefits, and treatment duration implications.

Wellness & Lifestyle

It’s Melanoma — Here’s What to Do Next

By MedXY 08/13/2025

Understand melanoma, its signs, and the importance of early detection and testing to combat skin cancer effectively.

Clinical Updates Wellness & Lifestyle

EBIN Study: Sequencing Targeted Therapy and Immunotherapy in BRAFV600-Mutant Advanced Melanoma

By MedXY 08/03/2025

A phase 2 trial found that induction targeted therapy with encorafenib and binimetinib before immune checkpoint inhibitors did not improve progression-free survival versus immune checkpoint inhibitors alone in advanced melanoma with BRAFV600E/K mutations.